Analysis of Adherence & Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin® Gel 0.1%
Phase 4
Completed
- Conditions
- Acne
- Registration Number
- NCT00437151
- Lead Sponsor
- Galderma R&D
- Brief Summary
The primary objective of this study is to investigate potential differences in treatment adherence by teenagers among four interventions during treatment for acne.
- Detailed Description
Same as above.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 61
Inclusion Criteria
- Adolescent subjects with a diagnosis of moderate to severe Acne vulgaris
Exclusion Criteria
- Subjects with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), or severe acne requiring more than topical treatment (e.g. oral isotretinoin)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Efficacy - Percent adherence calculated from MEMS Caps readings 12 weeks
- Secondary Outcome Measures
Name Time Method Efficacy - lesion counts; percent adherence as calculated by product weights and by Subject's Diary; Global Severity Assessment; Global Assessment of Improvement; Subject questionnaire 12 weeks Safety - tolerability and adverse event reporting 12 weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Differin® Gel 0.1%'s efficacy in acne vulgaris treatment among adolescents?
How does Differin® Gel 0.1% compare to other topical retinoids in adherence rates for moderate to severe acne?
Are there specific biomarkers that correlate with improved adherence to acne treatments in teenage populations?
What adverse events are commonly reported with adapalene gel in adolescent acne trials and how are they managed?
What combination therapies involving adapalene gel are being explored for enhanced acne vulgaris treatment outcomes?
Trial Locations
- Locations (1)
Wake Forest School of Medicine
🇺🇸Winston-Salem, North Carolina, United States
Wake Forest School of Medicine🇺🇸Winston-Salem, North Carolina, United States